Busulfan

Generic Name: Busulfan

Brand Names: Busulfex, Myleran, Busulfan Fresenius Kabi

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₆S_₂

CAS Number: 55-98-1

Unique Ingredient Identifier: G1LN9045DK

Background: Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication: For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions: Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

Phase 2

Conditions: Acute Lymphoblastic Leukemia, Adult

Interventions: Drug: Gemcitabine
Drug: Busulfan
Drug: Cyclophosphamide
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2017-11-13

Last Posted Date: 2020-01-14

Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Target Recruit Count: 15

Registration Number: NCT03339700

Locations: 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Phase 1

Conditions: X-Linked Combined Immunodeficiency Diseases

Interventions: Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
Drug: Palifermin
Drug: Busulfan

First Posted Date: 2017-10-19

Last Posted Date: 2019-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 13

Registration Number: NCT03315078

Locations: 🇺🇸
Laboratory of Host Defenses (LHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, United States

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Phase 2

Terminated

Conditions: IDH1 Gene Mutation
Plasma Cell Myeloma
Secondary Myelofibrosis
ASXL1 Gene Mutation
EZH2 Gene Mutation
Primary Myelofibrosis
Anemia
IDH2 Gene Mutation
Recurrent Plasma Cell Myeloma
Thrombocytopenia

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-06

Last Posted Date: 2022-05-05

Lead Sponsor: University of Utah

Target Recruit Count: 6

Registration Number: NCT03303950

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions: Drug: Busulfan
Drug: Gemcitabine
Drug: Melphalan
Drug: Olaparib
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacokinetic Study
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2017-08-23

Last Posted Date: 2024-03-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT03259503

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Sorafenib
Drug: Tacrolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT03247088

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Phase 1

Terminated

Conditions: HLA-A*0201 Positive Cells Present
Sarcoma
Unresectable Malignant Neoplasm
Locally Advanced Malignant Neoplasm
NY-ESO-1 Positive

Interventions: Other: 18F-FHBG
Biological: Aldesleukin
Drug: Busulfan
Biological: Cellular Therapy
Procedure: Computed Tomography
Biological: Filgrastim
Drug: Fludarabine
Procedure: Leukapheresis
Drug: Plerixafor
Procedure: Positron Emission Tomography

First Posted Date: 2017-08-07

Last Posted Date: 2023-11-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT03240861

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Phase 4

Conditions: Thalassemia Major

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Methotrexate
Drug: Thymoglobulin
Drug: Basiliximab

First Posted Date: 2017-05-31

Last Posted Date: 2017-05-31

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 30

Registration Number: NCT03171831

Locations: 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

Phase 2

Conditions: Lymphoma

Interventions: Drug: Chidamide
Drug: Cladribine
Drug: gemcitabine
Drug: Busulfan
Procedure: Autologous hematopoietic stem cell transplantation

First Posted Date: 2017-05-12

Last Posted Date: 2018-07-18

Lead Sponsor: Sichuan University

Target Recruit Count: 93

Registration Number: NCT03151876

Locations: 🇨🇳
Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China
🇨🇳
General Hospital of Lanzhou military command, Lanzhou, Gansu, China
🇨🇳
Peking university third hospital, Beijing, Beijing, China

and more 15 locations

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

First Posted Date: 2017-04-25

Last Posted Date: 2024-01-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 38

Registration Number: NCT03128359

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Neuroblastoma

First Posted Date: 2017-04-25

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 724

Registration Number: NCT03126916

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 158 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy